Kardiovaskulære, farmakologiske sikkerhedsstudier samt kliniske fase I- studier indikerede, at Gadovist potentielt kan blokere for de kardielle kaliumkanaler og indvirke på den kardielle repolarisering, når det gives i doser, der er 3- 8 gange højere end de doser, der normalt gives til patienter.
Cardiovascular safety pharmacology studies as well as clinical phase I studies gave indication for a potential of Gadovist to block cardiac potassium channels and an effect on cardiac repolarization when administered in doses 3 to 8fold higher than normally administered to patients.